PBLS - Latest News
Parabilis Medicines, Inc. (PBLS), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $4.56B. Beta to the broader market is 0.00.
The article list below shows the most recent PBLS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent PBLS Headlines
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.
globenewswire.com - Aug 25, 2026
CAMBRIDGE, Mass. , Aug.
Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform
seekingalpha.com - Aug 14, 2026
Parabilis Medicines (PBLS) leverages rare, genetically simple tumors to validate its Helicon platform, aiming for broader oncology applications. PBLS
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com - Aug 13, 2026
Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors
Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More
247wallst.com - Jul 6, 2026
Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and inve
This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
benzinga.com - Jul 6, 2026
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades
How News Affects PBLS Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track PBLS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked PBLS news questions
- What is the latest PBLS news headline?
- The most recent PBLS headline (Aug 25, 2026) is "Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the PBLS news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What PBLS news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual PBLS options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.